[Skip to Content]
[Skip to Content Landing]
Comment & Response
June 2014

Too Few Medicines for Children With Cancer

Author Affiliations
  • 1European Medicines Agency, London, United Kingdom
  • 2Department of Paediatric Oncology, Antwerp University Hospital (UZA), Edegem, Belgium
  • 3Department of Medicine and Health Sciences, Antwerp University, Wilrijk, Belgium

Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Pediatr. 2014;168(6):583. doi:10.1001/jamapediatrics.2014.15

To the Editor We welcome the Viewpoint by Adamson1 on how regulatory agencies can improve the health of children through requirements and incentives for pediatric cancer medicines. This is done at the European Medicines Agency by the Pediatric Committee, which has overseen pediatric investigation plans (PIPs) since 2007.2 However, we do not share Dr Adamson’s views on 2 points.

First Page Preview View Large
First page PDF preview
First page PDF preview